High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated im...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/?tool=EBI |
| _version_ | 1811222177578483712 |
|---|---|
| author | Irina Kadyrova Sergey Yegorov Baurzhan Negmetzhanov Yevgeniya Kolesnikova Svetlana Kolesnichenko Ilya Korshukov Lyudmila Akhmaltdinova Dmitriy Vazenmiller Yelena Stupina Naylya Kabildina Assem Ashimova Aigul Raimbekova Anar Turmukhambetova Matthew S. Miller Gonzalo Hortelano Dmitriy Babenko |
| author_facet | Irina Kadyrova Sergey Yegorov Baurzhan Negmetzhanov Yevgeniya Kolesnikova Svetlana Kolesnichenko Ilya Korshukov Lyudmila Akhmaltdinova Dmitriy Vazenmiller Yelena Stupina Naylya Kabildina Assem Ashimova Aigul Raimbekova Anar Turmukhambetova Matthew S. Miller Gonzalo Hortelano Dmitriy Babenko |
| author_sort | Irina Kadyrova |
| collection | DOAJ |
| description | COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response. |
| first_indexed | 2024-04-12T08:11:48Z |
| format | Article |
| id | doaj.art-fae6277fc5c64d8fa817e276af807d4f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T08:11:48Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-fae6277fc5c64d8fa817e276af807d4f2022-12-22T03:40:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01177High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccinationIrina KadyrovaSergey YegorovBaurzhan NegmetzhanovYevgeniya KolesnikovaSvetlana KolesnichenkoIlya KorshukovLyudmila AkhmaltdinovaDmitriy VazenmillerYelena StupinaNaylya KabildinaAssem AshimovaAigul RaimbekovaAnar TurmukhambetovaMatthew S. MillerGonzalo HortelanoDmitriy BabenkoCOVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/?tool=EBI |
| spellingShingle | Irina Kadyrova Sergey Yegorov Baurzhan Negmetzhanov Yevgeniya Kolesnikova Svetlana Kolesnichenko Ilya Korshukov Lyudmila Akhmaltdinova Dmitriy Vazenmiller Yelena Stupina Naylya Kabildina Assem Ashimova Aigul Raimbekova Anar Turmukhambetova Matthew S. Miller Gonzalo Hortelano Dmitriy Babenko High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination PLoS ONE |
| title | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
| title_full | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
| title_fullStr | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
| title_full_unstemmed | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
| title_short | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
| title_sort | high sars cov 2 seroprevalence in karaganda kazakhstan before the launch of covid 19 vaccination |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/?tool=EBI |
| work_keys_str_mv | AT irinakadyrova highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT sergeyyegorov highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT baurzhannegmetzhanov highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT yevgeniyakolesnikova highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT svetlanakolesnichenko highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT ilyakorshukov highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT lyudmilaakhmaltdinova highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT dmitriyvazenmiller highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT yelenastupina highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT naylyakabildina highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT assemashimova highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT aigulraimbekova highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT anarturmukhambetova highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT matthewsmiller highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT gonzalohortelano highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT dmitriybabenko highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination |